Citigroup
RKDA icon

Citigroup’s Arcadia Biosciences RKDA Stock Holding History

Citigroup’s Portfolio RKDA Stock Details RKDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1 Hold
1
– – ﹤0.01% 5869
2025
Q4 		$2 Sell
1
-355
-100% -$1.31K ﹤0.01% 5936
2025
Q3 		$1.24K Buy
+356
New +$1.46K ﹤0.01% 5595
2022
Q2 		– Sell
-204
Closed -$11K – 6588
2022
Q1 		$11K Buy
+204
New +$9.73K ﹤0.01% 5485
2016
Q2 		– Sell
-8
Closed -$19K – 7372
2016
Q1 		$19K Buy
8
+5
+167% +$10.6K ﹤0.01% 6573
2015
Q4 		$7K Buy
+3
New +$7.81K ﹤0.01% 6935
2015
Q3 		– Hold
0
– – – 7657
2015
Q2 		– Hold
0
– – – 7321

Other funds holding RKDA

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Citigroup's RKDA Position: Q1 2026 in Review

Citigroup held its Arcadia Biosciences (RKDA) position steady in Q1 2026 at 1 share worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #5869.

Citigroup first reported a position in RKDA in Q4 2015 and has held it in 6 quarters since. The position peaked at $19K in Q1 2016. 16 funds tracked by Wall St. Rank hold RKDA as of Q1 2026.

  • Citigroup held 1 share of Arcadia Biosciences worth $1 as of Q1 2026.
  • Citigroup left its Arcadia Biosciences share count unchanged in Q1 2026.
  • Arcadia Biosciences made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5869 holding.
  • Citigroup first reported a position in Arcadia Biosciences in Q4 2015 and has held it in 6 quarters since.
  • Citigroup's Arcadia Biosciences position peaked at $19K in Q1 2016.
  • 16 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.